Emma B Holliday1, Nathan F Dieckmann2, Tasha L McDonald3, Arthur Y Hung3, Charles R Thomas3, Lisa J Wood4. 1. The University of Texas MD Anderson Cancer Center Division of Radiation Oncology, Houston, United States. 2. Oregon Health & Science University School of Nursing, Department of Public Health and Preventative Medicine & Department of Psychiatry, Portland, United States. 3. Oregon Health & Science University Department of Radiation Medicine, Portland, United States. 4. The University of Texas MD Anderson Cancer Center Division of Radiation Oncology, Houston, United States; Massachussettes General Hospital Institute of Health Professions, Boston, United States. Electronic address: ljwood@mghihp.edu.
Abstract
BACKGROUND AND PURPOSE: Mechanisms of fatigue reported during radiotherapy are poorly defined but may include inflammatory cytokines and/or sleep disturbances. This prospective, longitudinal, phase II study assessed fatigue, sleep, and serum cytokine levels during radiotherapy for early-stage prostate cancer (PCa). MATERIAL AND METHODS: Twenty-eight men undergoing radiotherapy for early-stage PCa wore an Actiwatch Score to record fatigue level, sleep time, onset latency, efficiency and wake after sleep onset. Serum levels of IL-1α, IL-1β, TNF-α, IL-6, IL-8, IL-10 and VEGF were measured weekly during radiotherapy. Patient reported quality of life (QOL) metrics were collected before and after treatment. Linear mixed effects models examined trajectories across treatment weeks. RESULTS: Fatigue increased across treatment weeks (P<.01), and fatigue was associated with decreased patient-reported QOL. Sleep efficiency increased across treatment weeks (rate of change over time=.29, P=.03), and sleep onset latency decreased (rate of change over time=.86, P=.06). IL-6 tended to increase during treatment (P=0.09), but none of the cytokine levels or sleep variables were significantly related to fatigue trajectories. CONCLUSIONS: Despite increased sleep efficiency across treatment weeks, fatigue significantly increased. Although IL-6 increased during the course of radiotherapy, cytokines levels were not associated with fatigue scores or sleep disturbance. Further studies are needed to define the mechanisms for fatigue during radiotherapy.
BACKGROUND AND PURPOSE: Mechanisms of fatigue reported during radiotherapy are poorly defined but may include inflammatory cytokines and/or sleep disturbances. This prospective, longitudinal, phase II study assessed fatigue, sleep, and serum cytokine levels during radiotherapy for early-stage prostate cancer (PCa). MATERIAL AND METHODS: Twenty-eight men undergoing radiotherapy for early-stage PCa wore an Actiwatch Score to record fatigue level, sleep time, onset latency, efficiency and wake after sleep onset. Serum levels of IL-1α, IL-1β, TNF-α, IL-6, IL-8, IL-10 and VEGF were measured weekly during radiotherapy. Patient reported quality of life (QOL) metrics were collected before and after treatment. Linear mixed effects models examined trajectories across treatment weeks. RESULTS:Fatigue increased across treatment weeks (P<.01), and fatigue was associated with decreased patient-reported QOL. Sleep efficiency increased across treatment weeks (rate of change over time=.29, P=.03), and sleep onset latency decreased (rate of change over time=.86, P=.06). IL-6 tended to increase during treatment (P=0.09), but none of the cytokine levels or sleep variables were significantly related to fatigue trajectories. CONCLUSIONS: Despite increased sleep efficiency across treatment weeks, fatigue significantly increased. Although IL-6 increased during the course of radiotherapy, cytokines levels were not associated with fatigue scores or sleep disturbance. Further studies are needed to define the mechanisms for fatigue during radiotherapy.
Authors: Michael D Wirth; Desta Fekedulegn; Michael E Andrew; Alexander C McLain; James B Burch; Jean E Davis; James R Hébert; John M Violanti Journal: J Sleep Res Date: 2021-12-29 Impact factor: 5.296
Authors: R Lobefaro; S Rota; L Porcu; C Brunelli; S Alfieri; E Zito; I Taglialatela; M Ambrosini; A Spagnoletti; M Zimatore; G Fatuzzo; F Lavecchia; C Borreani; G Apolone; F De Braud; M Platania Journal: ESMO Open Date: 2022-03-31
Authors: Li Rebekah Feng; Brian S Wolff; Josephine Liwang; Jeniece M Regan; Sarah Alshawi; Sumiyya Raheem; Leorey N Saligan Journal: Int J Mol Med Date: 2019-12-18 Impact factor: 4.101